

Synergistic Effect of *Areca catechu* L. Ethanolic Extract and Its Chloroform Fraction with Doxorubicin on MCF7

EDY MEIYANTO*, SRI HANDAYANI, ENDAH PUJI SEPTISETYANI,
RATNA ASMAH SUSIDARTI

Cancer Chemoprevention Research Center,
Faculty of Pharmacy, Gadjah Mada University 55281

Accepted June 18th 2008, Approved March 17th 2009

Abstrak: Ekstrak etanol biji buah pinang (*Areca catechu* L.) menunjukkan efek sitotoksik pada sel kanker MCF7 dan WiDr. Penelitian ini bertujuan untuk mempelajari efek sinergisme antara ekstrak etanol biji buah pinang (AE) dan fraksi kloroformnya (ACF) dengan doxorubicin (Dox) dalam pemacu apoptosis sel MCF7. Ekstrak etanol dipartisi dengan *n*-heksan dan kloroform untuk mendapatkan fraksi kloroform. Efek sitotoksik AE, ACF, dan Dox pada perlakuan tunggal dan kombinasi ditentukan dengan metode MTT. Pengamatan apoptosis dilakukan dengan pengecatan DNA dengan akridin oranye-etidium bromida (*double staining*). Imunositokimia dilakukan untuk melihat ekspresi COX-2 dan Bax. Kombinasi Dox 100, 250, 334, dan 500 nM dengan AE 8 µg/ml; Dox 100 nM dengan AE 20 µg/ml; serta Dox 100 dan 250 nM dengan ACF 7 dan 18 µg/ml memperlihatkan efek sinergistis yang kuat (CI 0,1–0,3). Sementara itu, kombinasi Dox 250, 334, dan 500 nM dengan AE 20, 27, dan 40 µg/ml; Dox 100 nM dengan AE 27 dan 40 µg/ml; Dox 100 nM dengan AE 20 µg/ml; serta 500 nM dengan ACF 24 dan 35 µg/ml menunjukkan efek sinergistis (CI 0,3–0,7). Secara keseluruhan, kombinasi AE dan ACF dengan Dox memperlihatkan efek sinergistis pada MCF7 dengan indeks kombinasi (CI) kurang dari 0,9 ($P < 0,05$). Perlakuan kombinasi juga memacu apoptosis. Penekanan ekspresi Bcl-2 terjadi pada perlakuan kombinasi ACF-Dox. Hasil penelitian ini menunjukkan bahwa kombinasi AE dan ACF dengan Dox memberikan efek sinergistis dalam pemacu apoptosis dengan kemungkinan mekanisme melalui penekanan ekspresi Bcl-2.

Kata kunci: *Areca catechu*, kombinasi, sel MCF7, apoptosis, Bcl-2.

INTRODUCTION

CELL cycle arrest and apoptosis induction are two of the prospective strategies on cancer therapy⁽¹⁾. The cells are arrested to repair any damages which occur during cell cycle. Cells undergo apoptosis omitting the abnormal cells in order to maintain the balance of cell growth and the other normal biological processes⁽²⁾. The capabilities of the chemotherapeutic agents to induce cell cycle arrest and apoptosis on cancer cells determine its potency as cytotoxic agent⁽³⁾.

Doxorubicin is one of chemotherapeutic agent which commonly used in breast cancer therapy⁽⁴⁾. Doxorubicin performs high capability to induce apoptosis⁽⁵⁾. However, doxorubicin administration caused various side effects, such as myelosuppression, immunosuppression, and cardiac

toxicity^(6,7). Doxorubicin also induces cancer cell resistance through activation of *multidrug resistance* (MDR) gene leading to the decrease of cancer cell sensitivity against doxorubicin. Therefore, the finding of agents which increase cancer cell sensitivity is important to give more effective treatment and reduce side effects.

Previous study showed that *A. catechu* ethanolic extract and its chloroform fraction inhibit cell growth and induce apoptosis on MCF7 and WiDr cells^(8,9,10). Moreover, *Areca* chloroform fraction (ACF) performs apoptosis induction by suppressing of Bcl-2 expression on MCF7⁽⁹⁾, a chemotherapeutic resistant cell line^(11,12). The ACF possibly increases the sensitivity of resistant cancer cells against chemotherapeutic agent.

MATERIALS AND METHODS

MATERIALS. *Areca* seeds were obtained from Balai Penelitian Tanaman Obat (BPTO), Indonesia.

* Penulis korespondensi, Hp. 08122735092
e-mail: edy.meiyanto@gmail.com

Areca seeds ethanolic extract (AE) was prepared by extraction using ethanol. The chloroform fraction (ACF) was prepared by extracting AE using *n*-hexane and chloroform. MCF7 cell line obtained from Prof. Tatsuo Takeya (*Nara Institute of Science and Technology*, Japan) was cultured in DMEM medium (Gibco) with 10% Fetal Bovine Serum (Gibco) and 1% Penicillin-Streptomycin (Gibco). Monoclonal antibody anti-Bcl-2 was purchased from Dako, hydrochloric acid (HCl) and isopropanol were purchased from Merck, dimethylsulfoxide (DMSO), MTT [3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl-tetrazolium bromide], and other chemicals were purchased from Sigma.

METHODS. Cell viability assay. Cell viability was determined by using MTT assay. MCF7 cells (3×10^3 cells/well) were distributed onto 96 well-plates and incubated at 37°C for 48 hours. Serial dilution of the doxorubicin to calculate IC₅₀ were used at 100–1000 nM. Serial dilution of the AE, ACF and Doxorubicin (Dox) to calculate CI were used at 1/10, 1/4, 1/3, and 1/2 of IC₅₀. After rinsed the cells using phosphate buffer saline (PBS), cells were treated with the samples and after 48 hours incubation MTT reagent was added. Stopper reagent (hydrochloric acid 4N–isopropanol, 1:100) was added after formazan formation prior to MTT reduction. The absorbance of each well was measured using ELISA reader (Bio-Rad) at 595 nm.

Apoptosis assay. After 48 hours incubation at 37°C, MCF7 cells (5×10^4 cells/well) were treated with AE (60 µg/ml), ACF (60 µg/ml), Dox (500 nM) and combination of Dox-AE and Dox-ACF for 48 hours. After incubation, cells were stained for 5 minutes with acrydine orange–ethidium bromide staining solution (each 5 µg/ml in PBS) and viewed immediately by fluorescence microscope (Zeiss MC 80). Apoptotic cells which had lost their membrane integrity appeared orange and showed morphological features of apoptosis. Cells were identified as apoptotic on the basis of specific morphological criteria, including condensation and fragmentation of chromatin, and formation of apoptotic bodies.

Immunocytochemistry assay. MCF7 cells (5×10^4 cells/well) were seeded onto coverslip in 24 well-plates. Following 48 hours incubation at 37°C, cells were treated with ACF (60 µg/ml), Dox (500 nM) and combination of Dox-ACF for 15 hours. The cells attached on coverslip's surface were been treated with immunocytochemistry reagent according to the manufacturer's protocol. Cells were observed by using light microscope (Zeiss). The brown color of cytoplasm indicates positive expression while blue/violet indicates negative expression.

Statistical analysis. The absorbances were converted into percentage of cell viabilities and analyzed by using Excell MS Office 2003 and probit analysis (SPSS 11.5) to obtain IC₅₀ value. One-way Anova was used to assess the significance among the treatment (P<0.05) and post-hoc test was done using Tukey's Significant Differences test.

Concentration ratio of combinatorial treatment was used under IC₅₀ (Table 1). The cell viabilities of the combinations were used to determine *Combination Index* (CI) using the following equation:

$$CI = (D)_1 / (Dx)_1 + (D)_2 / (Dx)_2$$

D is the applied concentration and Dx is the calculating concentration which inhibits "x" percent of cell growths in combinatorial treatments. The various degrees of synergism or antagonism have been interpreted by using CI values (Table 2)⁽¹³⁾.

In apoptosis observation, at least 100 cells were evaluated to determine the percentage of apoptosis induction.

Table 1. Concentration ratio of the combination treatment.

Doxorubicin (IC ₅₀)	AE or ACF (IC ₅₀)			
	1/10	1/4	1/3	1/2
1/10	1/10 : 1/10	1/10 : 1/4	1/10 : 1/3	1/10 : 1/2
1/4	1/4 : 1/10	1/4 : 1/4	1/4 : 1/3	1/4 : 1/2
1/3	1/3 : 1/10	1/3 : 1/4	1/3 : 1/3	1/3 : 1/2
1/2	1/2 : 1/10	1/2 : 1/4	1/2 : 1/3	1/2 : 1/2

Table 2. Interpretation of CI values⁽¹³⁾

CI	Interpretation	CI	Interpretation
<0.1	very strong synergism	0.9–1.1	nearly additive
0.1–0.3	strong synergism	1.1–1.45	slight to moderate antagonism
0.3–0.7	synergism	1.45–3.3	antagonism
0.7–0.9	moderate to slight synergism	>3.3	strong to very strong antagonism

RESULTS AND DISCUSSIONS

Synergistic effect of AE and ACF with Dox. The result showed that cytotoxic effect represented in IC₅₀ value of Dox on MCF7 cell was 957 nM (data not shown). Previous study showed that IC₅₀ values of AE and ACF are 75µg/ml and 65µg/ml

respectively⁽⁹⁾. Both of them are potential to increase MCF7 sensitivity against dox, the commonly used chemotherapeutic agent on breast cancer treatment. Furthermore, calculation of synergistic effect of Dox-AE and Dox-ACF with CI parameter showed that all of the combination performed synergistic effects ($CI < 0.9$). Combination of AE (8, 20, 27 and 40 $\mu\text{g/ml}$) and ACF (7, 18, 24 and 35 $\mu\text{g/ml}$) with Dox (100, 250, 334, and 500 nM) inhibited MCF7 cells growth compared to single application in the same concentration (Figure 1A and 2A).

Based on the result, combination of 100, 250, 334, and 500 nM Dox with 8 $\mu\text{g/ml}$ AE; and 100 nM Dox with 20 $\mu\text{g/ml}$ AE showed strong synergistic effect ($CI 0.1-0.3$). Combination of 250, 334, and 500 nM Dox with 20, 27 and 40 $\mu\text{g/ml}$ AE; 100 nM Dox with 27 and 40 $\mu\text{g/ml}$ AE; and 100 nM Dox with 20 $\mu\text{g/ml}$ AE showed synergistic effect ($CI 0.3-0.7$) (Figure 1B; Table 3). The results suggested that

Dox-AE performed synergistic effect and indicated a better efficacy compared to the single application.

In Dox-ACF treatment, combination of 100 and 250 nM Dox with 7 and 18 $\mu\text{g/ml}$ ACF showed strong synergistic effect ($CI 0.1-0.3$). Moreover, combination of 100, 250, 334, and 500 nM Dox with 24 and 35 $\mu\text{g/ml}$ ACF showed synergistic effect ($CI 0.3-0.7$) (Figure 2B; Table 4). Taken together, the combination performed synergistic effect on MCF7 cells so that it is promising on combinatorial therapy.

Apoptotic effect of AE and ACF in combination with Dox. AE or ACF suggested to increase cells sensitivity against Dox. Apoptosis study showed that the Dox-AE and Dox-ACF combination increased apoptosis induction (Figure 3E-F) compared to the single application (Figure 3B-D). Apoptosis quantitative data showed that AE, ACF, Dox-AE and Dox-ACF treatment induced apoptosis on MCF7 cells 10.24, 17.89, 7.76, 23.29, and 23.47% respectively (Table 5).




Figure 1. Combinatorial effect of Dox-AE on cell growth inhibition. (A) Combination of AE (8–40 $\mu\text{g/ml}$) and Dox (100–500 nM) on cell viability. (B) Synergistic effect of Dox-AE with $CI < 0.9$. Combination Index (CI) was calculated as concentration ratio in single and combination treatments.




Figure 2. Combinatorial effect of Dox-ACF on cell growth inhibition. (A) Combination of ACF (7–35 $\mu\text{g/ml}$) and Dox (100–500 nM) on cell viability. (B) Synergistic effect of Dox-ACF with $CI < 0.9$. Combination Index (CI) was calculated as concentration ratio in single and combination treatments.

Table 3. CI values of Dox-AE combination.

AE concentration ($\mu\text{g/mL}$)	Dox concentration (nM)			
	100	250	334	500
8	0.15	0.26	0.25	0.27
20	0.29	0.35	0.34	0.38
27	0.43	0.34	0.36	0.41
40	0.42	0.37	0.47	0.51

Table 4. CI values of Dox-ACF combination.

ACF concentration ($\mu\text{g/mL}$)	Dox concentration (nM)			
	100	250	334	500
7	0.15	0.27	0.35	0.51
18	0.22	0.29	0.48	0.56
24	0.32	0.33	0.43	0.47
35	0.41	0.48	0.61	0.50




Figure 3. Dox-AE and Dox-ACF combination induced apoptosis on MCF7 cells. MCF7 cells (5×10^4) treated with AE (60 $\mu\text{g/mL}$), ACF (60 $\mu\text{g/mL}$) and Dox (500 nM) in single and combination for 48 h. (A) control cells, cells treated with (B) 500 nM Dox, (C) 50 $\mu\text{g/mL}$ AE, (D) 35 $\mu\text{g/mL}$ ACF, (E) Dox-AE (500 nM-50 $\mu\text{g/mL}$), and (F) Dox-ACF (500 nM-35 $\mu\text{g/mL}$). Cells were stained with acrydine orange-ethidium bromide and observed by using fluorescence microscope, 100x magnification, \longrightarrow apoptosis, \blacktriangleright viable cells.

Table 5. Apoptotic effects of Dox-AE and Dox-ACF against MCF7 cells.

No	Treatment	Apoptosis (%) [*]
1	Untreated cells	0
2	Dox 500 nM	7.76
3	AE 50 $\mu\text{g/mL}$	10.24
4	Dox-AE	23.29
5	ACF 35 $\mu\text{g/mL}$	17.89
6	Dox-ACF	23.47

Dox-ACF combination suppressed Bcl-2 expression. The result showed that 35 $\mu\text{g/mL}$ ACF seemingly suppressed Bcl-2 expression on MCF7 cells (Figure 4D) and 500nM Dox did not significantly suppress Bcl-2 expression compared to control cells (Figure 4C). The combination of Dox-ACF highly

suppressed Bcl-2 expression, significantly different to control cells (Figure 4E). These findings indicated that ACF may contribute on enhancement of Dox cytotoxicity through suppressing of Bcl-2 expression, leading to apoptosis induction.

DISCUSSIONS

MCF7 cell line is a resistant cell against several chemotherapeutic agent^(11,12). It is interesting that both Dox-AE and Dox-ACF combination showed synergistic effect on MCF7 cells (CI<0.9). This finding suggested that AE or ACF were promising to be combined with doxorubicin for breast cancer treatment. Apoptosis study showed that combination of Dox-AE and Dox-ACF induced apoptosis stronger than the single application. Furthermore, we investigated the possible mechanism mediated apoptosis induction of the combination.

MCF7 cell line overexpresses an antiapoptotic Bcl-2 protein^(14,15). Therefore, suppression of Bcl-2 expression by ACF on MCF7 cells (Figure 4) is a

prospective result for cancer treatment. Mechanism of *p53* dependent-apoptosis begins from the cellular stress followed by *p53* tumor suppressor gene expression. Expression of *p53* induces proapoptosis protein (such as Bad, Bax, and Bid) expression and cytochrome C release. This mechanism is inhibited by Bcl-2 which is expressed through the NF κ B-transcriptional activation⁽¹⁶⁾.

Flavonoid compounds in AE/ACF possibly mediate the inhibition of NF κ B activation. Flavonoids are potential inhibitor of protein kinases, such as IKK, which is important for NF κ B activation⁽¹⁷⁾. On the other hand, Dox induces DNA damage and followed by Fas-L expression. Fas-L in complex with Fas receptor activates caspase 8 leading to Bid activation to form tBid and followed by Bax




Figure 4. Bcl-2 expression after Dox-ACF treatment. MCF7 cells (5×10^4) treated with ACF (35 μ g/mL) and Dox (500 nM) in single and combination for 15 h. (A) cells without Bcl-2 antibody, (B) control cells, cells treated with (C) 500 nM Dox, (D) 35 μ g/mL ACF, and (E) Dox-ACF (500 nM Dox-35 μ g/mL), 400x magnification, - - \rightarrow positive, \rightarrow negative.




Figure 5. Possible synergistic mechanism of Dox-ACF inducing apoptosis. Dox induces DNA damage and followed by Fas-L expression. Fas-L in complex with Fas receptor activates caspase 8 leading to Bid activation to form tBid and followed by Bax localization on mitochondria outer membrane and increase cytochrome C release and then induce apoptosis. Suppression of Bcl-2 expression by ACF may increase sensitivity of MCF7 cells against doxorubicin on apoptosis induction.

localization on mitochondria outer membrane and increase cytochrome C release and then induce apoptosis. Suppression of Bcl-2 expression by ACF may increase sensitivity of MCF7 cells against doxorubicin on apoptosis induction (Figure 5).

CONCLUSIONS

The result showed that AE and ACF elevated sensitivity of MCF7 cells against doxorubicin. The combination performed synergistic effect to induce apoptosis. The research exhibited the relationship of synergistic effect of Dox-ACF and the suppression of Bcl-2 expression on MCF7 cells. Nevertheless, the exact mechanism remains unknown and needs further investigation.

ACKNOWLEDGEMENT

This work was supported by Hibah Bersaing XV, Direktorat Jenderal Pendidikan Tinggi (DIKTI).

REFERENCES

1. Daucas H, Garcea G, Neal CP, Manson MM, and Berry DP. Chemoprevention of pancreatic cancer: a review of the molecular pathways involved, and evidence for the potential for chemoprevention. *Pancreatology* 2006.6:429-39.
2. Wyllie A, Donahue V, Fischer B, Hill D, Keeseey J, and Manzow S. Cell death apoptosis and necrosis. Rosche Diagnostic Corporation. 2000.
3. Leigh MJ. Health benefits of grape seed proanthocyanidin extract (GSPE). *Nutrition Noteworthy* 2003.6(1):article 5.
4. Thurston DE and Lobo SGM. The chemotherapy of cancer, introduction to the principles of drug design and action. Australia: Harwood academic publishers; 1998.
5. Massart C, Barbet R, Genetet N, and Gibassier J. Doxorubicin induces Fas-mediated apoptosis in human thyroid carcinoma cells. *Thyroid* 2004. 14(4):263-70.
6. Tyagi AK, Agarwal C, Chan DCF, Agarwal R. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF7 and MDA-MB468 cells. *Oncology Reports*. 2004.11:493-9.
7. Wattanapitayakul SK, Chularojmontri L, Herunsalee A, Charuchongkolwongse S, Niumsakul S, and Bauer JA. Screening of antioxidants from medicinal plants for cardioprotective effect against doxorubicin toxicity. *Basic & Clin Pharm & Toxic*. 2005.96:80.
8. Meiyanto E, Susidarti RA, Handayani S, and Rahmi F. Ekstrak etanolik biji buah pinang (*Areca catechu* L.) sebagai agen kemopreventif pada sel kanker payudara resisten agen kemoterapi (MCF7). *Majalah Farmasi Indonesia*. 2008.19(1):12-19.
9. Meiyanto E, Handayani S, and Susidarti RA. Chloroform fraction of areca (*Areca catechu* L.) induce apoptosis and decrease Bcl-2 expression on MCF7 cells. 2008. Manuscript to be published..
10. Handayani S, Meiyanto E, and Susidarti RA. Areca (*Areca catechu* L.) seeds ethanolic extract and its chloroform fraction induce apoptosis and decrease COX-2 expression on WiDr cells. *Proceeding The International symposium on Molecular Targeted Therapy*. ISBN: 978-979-95107-6-1. Faculty of Pharmacy UGM; 2008. p. 67-74.
11. Menchetner E, Kyshtoobayeva A, Zonis S, Kim H, Stroup R, Garcia R, et al. Levels of multidrug resistance (mdr1) p-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. *Clin Can Res*. 1998.4:389-98.
12. Aouali N, Morjani H, Trussardi A, Soma E, Giroux B, and Manfait M. Enhanced cytotoxicity and nuclear accumulation of doxorubicin-loaded nanospheres in human breast cancer MCF7 cells expressing mrp1. *Int J Oncol*. 2003.23:1195-201.
13. Reynolds CP, and Maurer BJ. Evaluating response to antineoplastic drug combinations in tissue culture models. *Methods Mol Med* .2005.110:173-83.
14. Butt AJ, Firth SM, King MA, and Baxter RC. Insulin-like growth factor-binding protein-3 modulates expression of bax and bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. *J Biol Chem*. 2000. 275(50):39174-181.
15. Amundson SA, Myers TG, Scudiero D, Kitada S, Reed JC, and Fornace AJ. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. *Cancer Res*. 2000.60:6101-110.
16. Simstein R, Burow M, Parker A, Weldon C, and Beckman B. Apoptosis, chemoresistance, and breast cancer: insights from the MCF7 cell model system. *Exp Biol Med*. 2003.228:995-1003.
17. Sukla S, and Gupta S. Suppression of constitutive and tumor necrosis factor κ -induced nuclear factor (NF)- κ B activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells: correlation with down-regulation of NF- κ B-responsive genes. *Clin Can Res*. 2004.10:3169-178.